Murielle Veniant-Ellison, who heads Amgens obesity research and development, said that in addition to the drug binding to the GLP-1 receptor, its antibody also targets the GIP receptor, like tirzepatide
Under the pan-Canadian Pharmaceutical Alliance pricing structure, the first generic medication could be priced at 75 to 85 per cent of the brand-name list price [Source: glp1prices.ca/glp1-news/health-canada-reviewing-eight-more-generic-semaglutide-submissions-may-2026]
The clinical evidence behind them is unusually strong: in large randomized trials, semaglutide produced about 14.9% mean weight loss over 68 weeks and high-dose tirzepatide up to about 20.9% over 72 weeks
Your GP will take a thorough history, perform a clinical examination, and may arrange blood tests or other investigations as appropriate
Bone Health Concerns (Osteoporosis) One of the most serious but under-discussed long-term risks of GLP-1 medications is their potential impact on bone health
This likely relates to certain biological properties of vertical growth phase melanoma, specifically, the expression of transmembrane metalloproteinases which digest basement membrane material and facilitate the growth and spread of tumor
